Schwab Charles Investment Management Inc. increased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,160,497 shares of the biopharmaceutical company’s stock after purchasing an additional 201,109 shares during the quarter. Schwab Charles Investment Management Inc.’s holdings in Gilead Sciences were worth $369,699,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors have also modified their holdings of the company. Welch Investments LLC purchased a new position in shares of Gilead Sciences in the third quarter valued at about $108,000. Wealthcare Advisory Partners LLC purchased a new position in shares of Gilead Sciences in the third quarter valued at about $133,000. Horan Capital Advisors LLC. purchased a new position in shares of Gilead Sciences in the third quarter valued at about $144,000. Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of Gilead Sciences in the second quarter valued at about $147,000. Finally, Hanson & Doremus Investment Management increased its position in shares of Gilead Sciences by 806.5% in the third quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock valued at $147,000 after acquiring an additional 1,613 shares during the period. Institutional investors own 75.71% of the company’s stock.
A number of brokerages have recently weighed in on GILD. Mizuho lifted their target price on shares of Gilead Sciences from $77.00 to $83.00 and gave the company a “buy” rating in a research note on Wednesday, November 8th. JPMorgan Chase & Co. set a $85.00 target price on shares of Gilead Sciences and gave the company a “buy” rating in a research note on Wednesday, October 25th. Maxim Group set a $94.00 target price on shares of Gilead Sciences and gave the company a “buy” rating in a research note on Monday, December 11th. Credit Suisse Group reaffirmed a “buy” rating and set a $82.00 target price on shares of Gilead Sciences in a research note on Thursday, December 7th. Finally, Vetr lowered shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $90.00 target price on the stock. in a research note on Wednesday, January 17th. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the company. The company has an average rating of “Buy” and an average target price of $87.04.
In other news, insider John C. Martin sold 50,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $73.62, for a total value of $3,681,000.00. Following the transaction, the insider now owns 3,046,766 shares in the company, valued at $224,302,912.92. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Gayle E. Wilson sold 60,000 shares of the company’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $77.92, for a total transaction of $4,675,200.00. Following the completion of the transaction, the director now owns 182,258 shares in the company, valued at approximately $14,201,543.36. The disclosure for this sale can be found here. In the last quarter, insiders sold 418,333 shares of company stock worth $32,742,108. Insiders own 1.30% of the company’s stock.
Shares of Gilead Sciences, Inc. (NASDAQ GILD) opened at $80.94 on Wednesday. Gilead Sciences, Inc. has a 52 week low of $63.76 and a 52 week high of $89.54. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.48 and a current ratio of 3.55. The company has a market cap of $105,415.91, a PE ratio of 23.26, a P/E/G ratio of -1.85 and a beta of 1.22.
Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.67 by $0.11. The firm had revenue of $5.95 billion for the quarter, compared to the consensus estimate of $5.71 billion. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. The business’s revenue was down 18.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.70 earnings per share. analysts expect that Gilead Sciences, Inc. will post 6.24 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, March 29th. Stockholders of record on Friday, March 16th will be paid a $0.57 dividend. This represents a $2.28 annualized dividend and a dividend yield of 2.82%. The ex-dividend date is Thursday, March 15th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.52. Gilead Sciences’s dividend payout ratio is currently 59.77%.
COPYRIGHT VIOLATION NOTICE: “Schwab Charles Investment Management Inc. Has $369.70 Million Position in Gilead Sciences, Inc. (GILD)” was originally posted by Stock Observer and is the property of of Stock Observer. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://www.thestockobserver.com/2018/02/21/schwab-charles-investment-management-inc-has-369-70-million-position-in-gilead-sciences-inc-gild.html.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.